Female ; Humans ; Breast Neoplasms ; Testosterone ; Prolactin ; Estradiol ; Testosterone Congeners ; China

PURPOSE: To evaluate the actual impact of testosterone replacement therapy (TRT) on patients with lower urinary tract symptom (LUTS), without benign prostate hyperplasia (BPH) medication. MATERIALS AND METHODS: Two hundreds forty-six patients underwent TRT using intramuscular injection of 3 months bases injection of testosterone 100 mg undecanoate over a year. Among them, 17 patients had moderate LUTS with a maximal flow rate of at least 10 ml/s but did not take any BPH-specific medication during TRT. The changes in prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), and uroflowmetery were measured before and after TRT. RESULTS: After TRT, PSA remained unchanged after a year of treatment (p=0.078). Compared with their counterparts (n=229), the patients without BPH medication had similar baseline prostate characteristics in all variables, including prostate volume, IPSS, maximal flow rate, voiding volume, and PSA, except the median amount of residual urine, which was higher in the patients without BPH medication (21 ml vs. 10 ml). In the no-BPH medication group, the total IPSS score was decreased significantly (p=0.028), both in storage symptoms (questionnaire 2, 4, 7) and voiding symptoms (questionnaire 1, 3, 5, 6), while the maximal flow rate and residual urine amount remained unchanged after a year of TRT. During the median follow up of 15.1 months, no patients experienced urinary retention, BPH-related surgery, or admission for urinary tract infection. CONCLUSIONS: Over a year of TRT for the no-BPH medication patients with moderate LUTS and maintained a relatively high maximal flow rate and improved both storage and voiding symptoms, without the clinical progression of BPH or rising PSA.
Follow-Up Studies ; Humans ; Hyperplasia ; Injections, Intramuscular ; Lower Urinary Tract Symptoms ; Prostate ; Prostate-Specific Antigen ; Prostatic Hyperplasia ; Testosterone ; Testosterone Congeners ; Urinary Retention ; Urinary Tract

OBJECTIVE: The aim of this study was to measure maternal plasma androgens, estrogen and leptin levels and to assess the role of these hormones in the pathogenesis of preeclampsia. METHODS: The groups consisted of 32 healthy pregnant women as well as 28 pregnant women with severe preeclampsia. Plasma leptin, total testosterone (T), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS) and androstenedione (ADD) levels were measured. Statistical analysis was achieved with Student's t-test by using SPSS for Windows and the Pearson's coefficient of correlation was calculated. RESULTS: No significant differences were observed between the two groups regarding age, gestational age, body mass index, parity, hematocrit and platelet, whereas significant differences were noted regarding systolic and diastolic blood pressure, gestational weeks at delivery, birth weight, serum creatinine, uric acid and urea (p<0.05). In preeclampsia group, serum total testosterone and ADD levels were determined to be higher than the control group (p<0.05). However, there was no significant differences in plasma levels of DHEAS and E2 among the two groups. The plasma levels of leptin were not significantly increased in the preeclampsia group. Serum testosterone levels were positively correlated with systolic and diastolic pressure and uric acid and negatively correlated with birth weight. CONCLUSION: These results suggest that the elevated plasma levels of testosterone could contribute to the pathogenesis of preeclampsia.
Androgens ; Androstenedione ; Birth Weight ; Blood Platelets ; Blood Pressure ; Body Mass Index ; Creatinine ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Estradiol ; Estrogens ; Female ; Gestational Age ; Gonadal Steroid Hormones* ; Hematocrit ; Humans ; Leptin* ; Parity ; Plasma* ; Pre-Eclampsia* ; Pregnant Women ; Testosterone ; Urea ; Uric Acid

OBJECTIVE: The aim of this study was to measure maternal plasma androgens, estrogen and leptin levels and to assess the role of these hormones in the pathogenesis of preeclampsia. METHODS: The groups consisted of 32 healthy pregnant women as well as 28 pregnant women with severe preeclampsia. Plasma leptin, total testosterone (T), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS) and androstenedione (ADD) levels were measured. Statistical analysis was achieved with Student's t-test by using SPSS for Windows and the Pearson's coefficient of correlation was calculated. RESULTS: No significant differences were observed between the two groups regarding age, gestational age, body mass index, parity, hematocrit and platelet, whereas significant differences were noted regarding systolic and diastolic blood pressure, gestational weeks at delivery, birth weight, serum creatinine, uric acid and urea (p<0.05). In preeclampsia group, serum total testosterone and ADD levels were determined to be higher than the control group (p<0.05). However, there was no significant differences in plasma levels of DHEAS and E2 among the two groups. The plasma levels of leptin were not significantly increased in the preeclampsia group. Serum testosterone levels were positively correlated with systolic and diastolic pressure and uric acid and negatively correlated with birth weight. CONCLUSION: These results suggest that the elevated plasma levels of testosterone could contribute to the pathogenesis of preeclampsia.
Androgens ; Androstenedione ; Birth Weight ; Blood Platelets ; Blood Pressure ; Body Mass Index ; Creatinine ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Estradiol ; Estrogens ; Female ; Gestational Age ; Gonadal Steroid Hormones* ; Hematocrit ; Humans ; Leptin* ; Parity ; Plasma* ; Pre-Eclampsia* ; Pregnant Women ; Testosterone ; Urea ; Uric Acid

OBJECTIVE: The aim of this study was to measure maternal plasma androgens and estrogen levels and to assess the role of these hormones in the pathogenesis of preeclampsia. METHODS: The groups consisted of 28 healthy pregnant women as well as 24 pregnant women with severe preeclampsia. Plasma total testosterone (T), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS) and androstenedione (ADD) levels were measured. Statistical analysis was achieved with Student's t-test by using SPSS for Windows and the Pearson's coefficient of correlation was calculated. RESULTS: No significant differences were observed between the two groups regarding age, gestational age, body mass index, parity, hematocrit and platelet, whereas significant differences were noted regarding systolic and diastolic blood pressure, gestational weeks at delivery, birth weight, serum creatinine, uric acid and urea. In preeclampsia group, serum total testosterone and ADD levels were determined to be higher than the control group (p<0.05). However, there was no significant differences in plasma levels of DHEAS and E2 among the two groups (p>0.05). Serum testosterone levels were positively correlated with systolic and diastolic pressure and uric acid and negatively correlated with birth weight. CONCLUSION: These results suggest that the elevated plasma levels of testosterone could contribute to the pathogenesis of preeclampsia.
Androgens ; Androstenedione ; Birth Weight ; Blood Platelets ; Blood Pressure ; Body Mass Index ; Creatinine ; Dehydroepiandrosterone ; Dehydroepiandrosterone Sulfate ; Estradiol ; Estrogens* ; Female ; Gestational Age ; Hematocrit ; Humans ; Parity ; Plasma* ; Pre-Eclampsia ; Pregnancy ; Pregnancy Trimester, Third* ; Pregnancy* ; Pregnant Women ; Testosterone ; Urea ; Uric Acid

Androgens control a broad range of physiological functions. The androgen receptor (AR), a steroid receptor that mediates the diverse biological actions of androgens, is a ligand inducible transcription factor. Abnormalities in the androgen signaling system result in many disturbances ranging from changes in gender determination and sexual development to psychiatric and emotional disorders. Androgen replacement therapy can improve many clinical conditions including hypogonadism and osteoporosis, but is limited by the lack of efficacious and safe therapeutic agents with easy delivery options. Recent progress in the area of gene regulation by steroid receptors and by selective receptor modulators provides an opportunity to examine if selective androgen receptor modulators (SARMs) could address some of the problems associated with current androgen therapy. Since the composition of the transcriptional initiation complex recruited by liganded AR determines the specificity of gene regulation, synthetic ligands aimed at initiating transcription of tissue and promoter specific genes offers hope for developing better androgen therapy. Establishment of assays that predict synthetic ligand activity is critical for SARM development. Advancement in high throughput compound screening and gene fingerprinting technologies, such as microarrays and proteomics, will facilitate and accelerate identification of effective SARMs.
Androgen Antagonists ; pharmacology ; Androgen Receptor Antagonists ; Androgens ; chemistry ; metabolism ; Chlormadinone Acetate ; analogs & derivatives ; pharmacology ; Humans ; Male ; Receptors, Androgen ; physiology ; Receptors, Cytoplasmic and Nuclear ; physiology ; Testosterone Congeners ; pharmacology

Androgen therapy has proven efficacy in treating patients with bone marrow failure who are not candidates for bone marrow transplantation. Herein, we report on a case of colonic angioectasia secondary to oxymetholone use in an adolescent patient with Hoyeraal-Hreidarsson syndrome (HHS). A 13-year-old Caucasian male with HHS characterized by cerebellar hypoplasia, developmental delay, microcephaly, esophageal strictures and myelodysplasia presented with severe hematochezia from colonic angioectasia secondary to long-term oxymetholone therapy. These vascular lesions resolved spontaneously once this anabolic steroid was discontinued. While androgen therapy is often recommended for certain anemias and myelodysplastic syndromes, clinicians should be aware of the potential complication in developing these perceived uncommon colonic angioectasias. Moreover, pediatric gastroenterologists should familiarize themselves in identifying these vascular lesions by colonoscopy, especially among the high risk groups on long-term anabolic steroid therapy.
Adolescent ; Anemia ; Bone Marrow ; Bone Marrow Transplantation ; Colon ; Colonoscopy ; Constriction, Pathologic ; Gastrointestinal Hemorrhage ; Humans ; Male ; Microcephaly ; Myelodysplastic Syndromes ; Oxymetholone ; Testosterone Congeners

To investigate the effects of the property of drugs and the structure of drug delivery devices on the drug release rate, the effects of sealing methods, length, thickness and drug-loading manner of the silicone tubes on the drug release rate were examined using progestin, testosterone, estradiol as the delivery drugs. The results showed that the property of the drug was the crucial factor to the drug release rate. The sealing methods, length, thickness and drug status of the silicone tubes had significant effects on the drug release rate and the effects were closely related to the property of the drugs. In addition, our newly developed glass-silicone tube has larger drug deposition capability and smaller drug release area, offers an effective and convenient method for the sustained drug delivery with quick release traits in vivo.
Delayed-Action Preparations ; chemistry ; Drug Carriers ; administration & dosage ; chemistry ; Drug Delivery Systems ; Estradiol ; administration & dosage ; Progesterone Congeners ; administration & dosage ; Silicones ; Testosterone ; administration & dosage

Testosterone (T) as a compound for treatment of T deficiency has been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable T esters have been used for treatment, but they generate supranormal T levels shortly after the 2-3 weekly injection interval. T levels then decline very rapidly, becoming subnormal during the days preceding the next injection. The rapid fluctuations in plasma T are subjectively experienced as disagreeable. T undecanoate (TU) is a new injectable T preparation with a considerably better pharmacokinetic profile. After two initial injections separated by a 6-week interval, the following intervals between two injections are generally 12 weeks, eventually amounting to a total of four injections per year. Plasma T levels with this preparation are nearly always in the range of normal men, as are its metabolic products estradiol and dihydrotestosterone (DHT). It reverses the effects of hypogonadism on bone and muscle and metabolic parameters, and on sex functions. It is suitable for male contraception. Its safety profile is excellent because of the continuous normalcy of plasma T levels. No polycythemia has been observed and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. TU is a valuable treatment option of androgen deficiency.
Contraceptive Agents, Male ; pharmacokinetics ; therapeutic use ; Erectile Dysfunction ; drug therapy ; Humans ; Hypogonadism ; drug therapy ; Injections, Intramuscular ; Male ; Testosterone ; analogs & derivatives ; blood ; pharmacokinetics ; therapeutic use ; Testosterone Congeners ; pharmacokinetics ; therapeutic use

OBJECTIVETo assess the utility of serum steroids measurement in monitoring the treatment of children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD).

METHODNineteen Patients with CAH 21OHD aged (3.67±1.54) years treated with hydrocortisone and fluorocortisone replacement were followed up at an intervals of 0.33 - 1.0 years over a period of (1.47±0.7) years. At each visit, roentgenograms of the hands and wrists were taken, fasting peripheral blood were collected to test serum dehydroepiandrosterone sulfate, progesterone, 17-hydroxyprogesterone (17-OHP), androstenedione (Δ4-A), testosterone, free testosterone, estrone, and estradiol concentrations at 8 AM in the morning before the first dose of glucocorticoid. Then the patients were classified as being in "Good Control" or in "Poor Control" based on clinical criteria including signs of androgen excess, growth velocity and bone age increment at each interval. Comparisons were carried out between the serum steroid concentrations of the two groups. The receiver operating characteristic (ROC) curves were used to determine the cut-off values for diagnosing "Poor Control".

RESULTBoth of serum Δ4-A and 17-OHP concentrations were higher in "Poor Control" group than those in "Good Control" group [5.95 (2.23-11.2) nmol/L versus 1.05 (1.05-9.89) nmol/L, t=2.19; 13.85 (6.06-20) µg/L versus 3.67 (0.42-21.1) µg/L, t=2.17; P<0.05, respectively]. The ROC curves for serum Δ4-A concentrations, serum 17-OHP concentrations, serum Δ4-A in combination with 17-OHP concentrations were constructed with areas under the ROC curves (95%CI) of 0.76 (0.62, 0.90), 0.75 (0.62, 0.88), 0.69 (0.54, 0.84), P<0.05, respectively. Serum Δ4-A of 3.9 nmol/L had 0.78 of sensitivity and 0.75 of specificity in diagnosing "Poor Control". Serum 17-OHP of 7.1 µg/L has 0.67 of sensitivity and 0.71 of specificity in diagnosing "Poor Control".

CONCLUSIONEach of serum 17-OHP or/and Δ4-A concentration was of significance in diagnosing "Poor Control" during the glucocorticoid replacement treatment of CAH 21OHD, with the diagnostic efficacy being serum Δ4-A concentration, serum 17-OHP concentration and serum Δ4-A in combination with 17-OHP concentration in descending order. Serum Δ4-A and 17-OHP concentrations may be used as the biochemical indicators to monitor the therapy of CAH 21OHD.

17-alpha-Hydroxyprogesterone ; blood ; Adrenal Hyperplasia, Congenital ; blood ; diagnosis ; therapy ; Androstenedione ; blood ; Child, Preschool ; Dehydroepiandrosterone Sulfate ; blood ; Female ; Humans ; Hydrocortisone ; blood ; Male ; Progesterone ; blood ; Steroid 21-Hydroxylase ; blood ; Testosterone ; blood